Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection

Background. Patient race and ethnicity have historically impacted HCV treatment response. This phase 3 study evaluated daclatasvir with peginterferon-alfa-2a/ribavirin (pegIFN alfa-2a/RBV) in treatment-naive black/African American (AA), Latino, and white non-Latino patients with chronic HCV genotype...

Full description

Bibliographic Details
Main Authors: Maribel Rodriguez-Torres, Eric Läwitz, Bienvenido Yangco, Lennox Jeffers, Steven-Huy Han, Paul J. Thuluvath, Vinod Rustgi, Stephen Harrison, Reem Ghalib, John M. Vierling, Velimir Luketic, Philippe J. Zamor, Natarajan Ravendhran, Timothy R. Morgan, Brian Pearlman, Christopher O’Brien, Hicham Khallafi, Nikolaos Pyrsopoulos, George Kong, Fiona McPhee, Philip D. Yin, Eric Hughes, Michelle Treitel
Format: Article
Language:English
Published: Elsevier 2016-11-01
Series:Annals of Hepatology
Subjects:
NS5A Inhibitor
Antiviral therapy
Liver disease
Ethnicity
Race
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119311093

Similar Items

Similar Items